Upregulation of the ligand-RAGE pathway via the angiotensin II type I receptor is essential in the pathogenesis of diabetic atherosclerosis

Yoshiko Ihara, Kensuke Egashira, Kaku Nakano, kisho ohtani, Mitsuki Kubo, Jun ichiro Koga, Masaru Iwai, Masatsugu Horiuchi, Zhao Gang, Sho ichi Yamagishi, Kenji Sunagawa

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

The receptor for advanced glycation end products (RAGE) and the angiotensin II type I receptor (AT1R) have been separately linked to the pathogenesis of diabetic atherosclerosis. However, no prior study has addressed a linkage between RAGE and AT1R in diabetic atherogenesis. Therefore, we tested the hypothesis that upregulation of the ligand-RAGE axis via AT1R is an essential process underlying the disease. Diabetes was induced in apolipoprotein E-deficient (ApoE-/-) mice by streptozotocin, and diabetic mice were treated with AT1 receptor blocker (ARB) for 6 weeks. Diabetic ApoE-/- mice that were AT1R-deficient (ApoE-/-AT1aR-/-) were also investigated. In diabetic ApoE-/- mice, AT1R was found to increase within 1 week of diabetes induction, before ligand-RAGE pathway activation and other inflammatory changes were observed. Both ARB treatment and AT1aR deficiency suppressed diabetic atherosclerosis, ligand-RAGE expression and inflammatory changes. In contrast, upregulation of the ligand-RAGE pathway was noted in atherosclerotic plaques from non-diabetic ApoE-/- mice infused with angiotensin II. In cultured vascular smooth muscle cells, angiotensin II increased RAGE protein levels via AT1R stimulation. Upregulation of the ligand-RAGE pathway via AT1R is an essential mechanism in diabetic atherosclerosis, implying that ARB might decrease diabetic atherogenesis by inhibiting ligand-RAGE signals.

Original languageEnglish
Pages (from-to)455-464
Number of pages10
JournalJournal of Molecular and Cellular Cardiology
Volume43
Issue number4
DOIs
Publication statusPublished - Oct 1 2007

Fingerprint

Angiotensin I
Angiotensin Receptors
Atherosclerosis
Up-Regulation
Ligands
Apolipoproteins E
Advanced Glycosylation End Product-Specific Receptor
Atherosclerotic Plaques
Streptozocin
Vascular Smooth Muscle
Angiotensin II
Smooth Muscle Myocytes

All Science Journal Classification (ASJC) codes

  • Molecular Biology
  • Cardiology and Cardiovascular Medicine

Cite this

Upregulation of the ligand-RAGE pathway via the angiotensin II type I receptor is essential in the pathogenesis of diabetic atherosclerosis. / Ihara, Yoshiko; Egashira, Kensuke; Nakano, Kaku; ohtani, kisho; Kubo, Mitsuki; Koga, Jun ichiro; Iwai, Masaru; Horiuchi, Masatsugu; Gang, Zhao; Yamagishi, Sho ichi; Sunagawa, Kenji.

In: Journal of Molecular and Cellular Cardiology, Vol. 43, No. 4, 01.10.2007, p. 455-464.

Research output: Contribution to journalArticle

Ihara, Yoshiko ; Egashira, Kensuke ; Nakano, Kaku ; ohtani, kisho ; Kubo, Mitsuki ; Koga, Jun ichiro ; Iwai, Masaru ; Horiuchi, Masatsugu ; Gang, Zhao ; Yamagishi, Sho ichi ; Sunagawa, Kenji. / Upregulation of the ligand-RAGE pathway via the angiotensin II type I receptor is essential in the pathogenesis of diabetic atherosclerosis. In: Journal of Molecular and Cellular Cardiology. 2007 ; Vol. 43, No. 4. pp. 455-464.
@article{948b43e7951248f38b9c0adf2b8c38b4,
title = "Upregulation of the ligand-RAGE pathway via the angiotensin II type I receptor is essential in the pathogenesis of diabetic atherosclerosis",
abstract = "The receptor for advanced glycation end products (RAGE) and the angiotensin II type I receptor (AT1R) have been separately linked to the pathogenesis of diabetic atherosclerosis. However, no prior study has addressed a linkage between RAGE and AT1R in diabetic atherogenesis. Therefore, we tested the hypothesis that upregulation of the ligand-RAGE axis via AT1R is an essential process underlying the disease. Diabetes was induced in apolipoprotein E-deficient (ApoE-/-) mice by streptozotocin, and diabetic mice were treated with AT1 receptor blocker (ARB) for 6 weeks. Diabetic ApoE-/- mice that were AT1R-deficient (ApoE-/-AT1aR-/-) were also investigated. In diabetic ApoE-/- mice, AT1R was found to increase within 1 week of diabetes induction, before ligand-RAGE pathway activation and other inflammatory changes were observed. Both ARB treatment and AT1aR deficiency suppressed diabetic atherosclerosis, ligand-RAGE expression and inflammatory changes. In contrast, upregulation of the ligand-RAGE pathway was noted in atherosclerotic plaques from non-diabetic ApoE-/- mice infused with angiotensin II. In cultured vascular smooth muscle cells, angiotensin II increased RAGE protein levels via AT1R stimulation. Upregulation of the ligand-RAGE pathway via AT1R is an essential mechanism in diabetic atherosclerosis, implying that ARB might decrease diabetic atherogenesis by inhibiting ligand-RAGE signals.",
author = "Yoshiko Ihara and Kensuke Egashira and Kaku Nakano and kisho ohtani and Mitsuki Kubo and Koga, {Jun ichiro} and Masaru Iwai and Masatsugu Horiuchi and Zhao Gang and Yamagishi, {Sho ichi} and Kenji Sunagawa",
year = "2007",
month = "10",
day = "1",
doi = "10.1016/j.yjmcc.2007.07.044",
language = "English",
volume = "43",
pages = "455--464",
journal = "Journal of Molecular and Cellular Cardiology",
issn = "0022-2828",
publisher = "Academic Press Inc.",
number = "4",

}

TY - JOUR

T1 - Upregulation of the ligand-RAGE pathway via the angiotensin II type I receptor is essential in the pathogenesis of diabetic atherosclerosis

AU - Ihara, Yoshiko

AU - Egashira, Kensuke

AU - Nakano, Kaku

AU - ohtani, kisho

AU - Kubo, Mitsuki

AU - Koga, Jun ichiro

AU - Iwai, Masaru

AU - Horiuchi, Masatsugu

AU - Gang, Zhao

AU - Yamagishi, Sho ichi

AU - Sunagawa, Kenji

PY - 2007/10/1

Y1 - 2007/10/1

N2 - The receptor for advanced glycation end products (RAGE) and the angiotensin II type I receptor (AT1R) have been separately linked to the pathogenesis of diabetic atherosclerosis. However, no prior study has addressed a linkage between RAGE and AT1R in diabetic atherogenesis. Therefore, we tested the hypothesis that upregulation of the ligand-RAGE axis via AT1R is an essential process underlying the disease. Diabetes was induced in apolipoprotein E-deficient (ApoE-/-) mice by streptozotocin, and diabetic mice were treated with AT1 receptor blocker (ARB) for 6 weeks. Diabetic ApoE-/- mice that were AT1R-deficient (ApoE-/-AT1aR-/-) were also investigated. In diabetic ApoE-/- mice, AT1R was found to increase within 1 week of diabetes induction, before ligand-RAGE pathway activation and other inflammatory changes were observed. Both ARB treatment and AT1aR deficiency suppressed diabetic atherosclerosis, ligand-RAGE expression and inflammatory changes. In contrast, upregulation of the ligand-RAGE pathway was noted in atherosclerotic plaques from non-diabetic ApoE-/- mice infused with angiotensin II. In cultured vascular smooth muscle cells, angiotensin II increased RAGE protein levels via AT1R stimulation. Upregulation of the ligand-RAGE pathway via AT1R is an essential mechanism in diabetic atherosclerosis, implying that ARB might decrease diabetic atherogenesis by inhibiting ligand-RAGE signals.

AB - The receptor for advanced glycation end products (RAGE) and the angiotensin II type I receptor (AT1R) have been separately linked to the pathogenesis of diabetic atherosclerosis. However, no prior study has addressed a linkage between RAGE and AT1R in diabetic atherogenesis. Therefore, we tested the hypothesis that upregulation of the ligand-RAGE axis via AT1R is an essential process underlying the disease. Diabetes was induced in apolipoprotein E-deficient (ApoE-/-) mice by streptozotocin, and diabetic mice were treated with AT1 receptor blocker (ARB) for 6 weeks. Diabetic ApoE-/- mice that were AT1R-deficient (ApoE-/-AT1aR-/-) were also investigated. In diabetic ApoE-/- mice, AT1R was found to increase within 1 week of diabetes induction, before ligand-RAGE pathway activation and other inflammatory changes were observed. Both ARB treatment and AT1aR deficiency suppressed diabetic atherosclerosis, ligand-RAGE expression and inflammatory changes. In contrast, upregulation of the ligand-RAGE pathway was noted in atherosclerotic plaques from non-diabetic ApoE-/- mice infused with angiotensin II. In cultured vascular smooth muscle cells, angiotensin II increased RAGE protein levels via AT1R stimulation. Upregulation of the ligand-RAGE pathway via AT1R is an essential mechanism in diabetic atherosclerosis, implying that ARB might decrease diabetic atherogenesis by inhibiting ligand-RAGE signals.

UR - http://www.scopus.com/inward/record.url?scp=34548843883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548843883&partnerID=8YFLogxK

U2 - 10.1016/j.yjmcc.2007.07.044

DO - 10.1016/j.yjmcc.2007.07.044

M3 - Article

C2 - 17761193

AN - SCOPUS:34548843883

VL - 43

SP - 455

EP - 464

JO - Journal of Molecular and Cellular Cardiology

JF - Journal of Molecular and Cellular Cardiology

SN - 0022-2828

IS - 4

ER -